Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin - PubMed (original) (raw)

Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin

Cristina González-Puga et al. J Pineal Res. 2005 Oct.

Abstract

Some data suggest that cholecystokinin (CCK) receptor agonists stimulate the growth of colon cancer. Melatonin, an endogenous indoleamine with strong antioxidant properties, displays antiproliferative and proapoptotic properties both in vivo or in vitro in several types of tumors. We used HT-29 human colon cancer cells, expressing CCK receptors, to test the antiproliferative effects of several antagonists of CCK-A and/or CCK-B and their possible synergism with melatonin. HT-29 cells were cultured in RPMI 1640 medium supplemented with fetal bovine serum at 37 degrees C. Cell proliferation was assessed by the incorporation of [3H]-thymidine into DNA. Annexin V-FITC plus propidium iodine were used for flow cytometry apoptosis/necrosis evaluation. The following drugs were tested: gastrin (CCK-B agonist); CCK-8s (CCK-A agonist); proglumide (CCK-A plus CCK-B antagonist); lorglumide (CCK-A antagonist); PD 135,158 (CCK-B antagonist and weak CCK-A agonist); devazepide or L 364,718 (CCK-A antagonist); L 365,260 (CCK-B antagonist), and melatonin. The results shown a lack of effects of gastrin on HT-29 cell proliferation, whereas CCK-8s induced proliferation at high doses. The order of the antiproliferative effect of the other drugs was devazepide > lorglumide > proglumide. These drugs produce cell death mainly inducing apoptosis. Melatonin showed strong antiproliferative effect at millimolar concentrations, and it induced apoptotic cell death. Melatonin generally enhanced the antiproliferative effects of devazepide, lorglumide and proglumide and increased the proglumide-induced apoptosis. These results suggest that melatonin and CCK-A antagonists are useful for controlling human colon cancer cell growth in culture and in combined therapy significantly increases their efficiency.

PubMed Disclaimer

Cited by

Computational Drug Repurposing for Alzheimer's Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies.
Xu Y, Kong J, Hu P. Xu Y, et al. Front Pharmacol. 2021 Jun 30;12:617537. doi: 10.3389/fphar.2021.617537. eCollection 2021. Front Pharmacol. 2021. PMID: 34276354 Free PMC article.
Devazepide suppresses cell proliferation and migration, and induces apoptosis in bladder carcinoma.
Zhang H, Bao X, Zhang J, Hu Q, Wei B. Zhang H, et al. Transl Androl Urol. 2021 May;10(5):2113-2121. doi: 10.21037/tau-21-409. Transl Androl Urol. 2021. PMID: 34159092 Free PMC article.
The role of melatonin in colorectal cancer treatment: a comprehensive review.
Kvietkauskas M, Zitkute V, Leber B, Strupas K, Stiegler P, Schemmer P. Kvietkauskas M, et al. Ther Adv Med Oncol. 2020 Jul 17;12:1758835920931714. doi: 10.1177/1758835920931714. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32733605 Free PMC article. Review.
Ex vivo human pancreatic slice preparations offer a valuable model for studying pancreatic exocrine biology.
Liang T, Dolai S, Xie L, Winter E, Orabi AI, Karimian N, Cosen-Binker LI, Huang YC, Thorn P, Cattral MS, Gaisano HY. Liang T, et al. J Biol Chem. 2017 Apr 7;292(14):5957-5969. doi: 10.1074/jbc.M117.777433. Epub 2017 Feb 27. J Biol Chem. 2017. PMID: 28242761 Free PMC article.
Expression of cholecystokinin receptors in colon cancer and the clinical correlation in Taiwan.
Huang BP, Lin CH, Chen YC, Kao SH. Huang BP, et al. Tumour Biol. 2016 Apr;37(4):4579-84. doi: 10.1007/s13277-015-4306-1. Epub 2015 Oct 27. Tumour Biol. 2016. PMID: 26508021

Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin - PubMed (original) (raw)